Page last updated: 2024-11-04

pseudohypericin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pseudohypericin is a natural compound found in plants of the Hypericum genus, such as St. John's Wort. It is a potent antioxidant and exhibits various pharmacological effects, including antiviral, anti-inflammatory, and anticancer activities. Pseudohypericin is synthesized through a complex biosynthetic pathway involving several enzymatic steps. Its unique structure, characterized by a highly conjugated system, allows for strong absorption of light, leading to its photodynamic properties. Researchers are interested in studying pseudohypericin for its potential therapeutic applications, particularly in treating viral infections, inflammatory diseases, and certain types of cancer. The compound has also been investigated for its neuroprotective and wound-healing properties.'

pseudohypericin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4978
SCHEMBL ID25982
MeSH IDM0158711

Synonyms (28)

Synonym
BIDD:PXR0086
bdbm50333880
HSCI1_000222
nsc-624609
nsc624609
psuedohypericin
SMP2_000351
hexahydroxy-(hydroxymethyl)-methyl-[?]dione
pseudohypericin
55954-61-5
phenanthro(1,10,9,8-opgra)perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10-(hydroxymethyl)-11-methyl-, stereoisomer
LMPK13040014
hsdb 8107
mq0u4663zo ,
unii-mq0u4663zo
FT-0645051
SCHEMBL25982
pseudohypericin (constituent of st. john's wort) [dsc]
phenanthro(1,10,9,8-opqra)perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10-(hydroxymethyl)-11-methyl-
Q-100649
DTXSID00204541
mfcd00133794
pseudohypericin, analytical standard
pseudohypericin, >=95% (hplc)
9,11,13,16,18,20-hexahydroxy-5-(hydroxymethyl)-24-methyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione
BCP15641
pseudohypericin , hplc grade
1,3,4,6,8,13-hexahydroxy-10-(hydroxymethyl)-11-methylphenanthro[1,10,9,8-opqra]perylene-7,14-dione

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The median elimination half-life times of hypericin were 24."( Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1994
)
0.57
" The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses."( Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1996
)
0.53
" Therefore, the objective of the two open phase I clinical trials was to obtain pharmacokinetic data of these constituents from a hypericum extract containing tablet: hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.77
" In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce."( Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Schubert-Zsilavecz, M; Wurglics, M, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce."( Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Schubert-Zsilavecz, M; Wurglics, M, 2006
)
0.33
" Interactions of constituents, tested in bioavailability models, may explain why synergistic mechanisms have been found to be important for antidepressant and antiproliferative bioactivities."( Evidence for contributions of interactions of constituents to the anti-inflammatory activity of Hypericum perforatum.
Birt, DF; Hammer, KD, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Viremia induced by LP-BM5 murine immunodeficiency virus is markedly suppressed after infrequent dosage of either substance."( Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin.
Gallo, G; Lavie, D; Lavie, G; Levin, B; Mazur, Y; Meruelo, D; Valentine, F; Weiner, D, 1989
)
0.5
" During long-term dosing (3 x 300 mg/day), a steady-state was reached after 4 days."( Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1994
)
0.57
" Concentration/time curves were determined for the five constituents, for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.35)18.7374
1990's10 (14.49)18.2507
2000's33 (47.83)29.6817
2010's22 (31.88)24.3611
2020's1 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.27 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (8.97%)5.53%
Reviews4 (5.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (85.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]